WASHINGTON: Wednesday, the US Centers for Disease Control and Prevention (CDC) announced that the monkeypox vaccination is very effective, protecting people as early as two weeks after the first dosage.
A preliminary analysis published by the FDA revealed that between July 31 and September 3, unvaccinated individuals had 14 times the risk of contracting monkeypox disease compared to those who were vaccinated 14 days or more after receiving their first vaccination.
The findings were based on confirmed cases in 32 jurisdictions across the nation. The latest outbreak, which began in May of this year and mostly affects men with physical interactions with other men, has resulted in more than 25,000 cases in the United States.
During a conference with media, CDC director Rochelle Walensky stated, “These new results provide us with cautious hope that the vaccine is functioning as planned.”
“Even in light of these encouraging results, we highly suggest that individuals take two doses of the Jynneos vaccination 28 days apart,” she noted.
Despite being authorized, there is no validated efficacy estimate for the Jynneos vaccine against monkeypox, as previous research only analyzed animal data and human immune response measurements.
Globally, about 66,000 cases of monkeypox have been identified, although since August, the rate of new infections has decreased.
The United States has provided about 680,000 doses of the Jynneos vaccine, targeting gay and bisexual men as well as transgender and gender-variant individuals.
Demetre Daskalakis, the deputy coordinator for the White House’s response to the outbreak of monkeypox, stated that the rollout strategy was entering a new phase in which the vaccine would be administered to individuals who had never been exposed to the virus, as opposed to those who had been exposed.
“This new technique means that more individuals who are at present or future risk for monkeypox are now eligible for the vaccine,” he said.
In order to decrease stigma, the new guidance would permit health care providers to deliver the vaccination in less visible regions, such as the shoulder or upper back, as opposed to the forearm, he noted.